Welcome to your daily round-up of everything happening in the world of neurorehabilitation.
Research news
Latest evidence on the diagnosis, treatment, and monitoring of ADHD
Hundreds of studies are published each year on attention deficit hyperactivity disorder (ADHD), but more work is needed to ensure those findings improve lives. With input from expert stakeholders across the field, researchers at the Southern California Evidence Review Center, part of the Keck School of Medicine of USC, have synthesized the latest insights so that they can ultimately inform clinical practice. Broadly, they found that both medications and psychosocial treatments work for treating ADHD and that children with the condition can and do get better.
How might diabetes lead to Alzheimer’s?
A new study has added to a growing body of research on the links between Type 2 diabetes and Alzheimer’s disease, which some scientists have called “Type 3 diabetes.” The findings suggest that it should be possible to reduce the risk of Alzheimer’s by keeping diabetes well controlled or avoiding it in the first place, according to researchers.
Importance of support reciprocity during early-stage dementia care
In cases of Alzheimer’s disease, it’s common for a spouse to take on the role of caregiver. Research led by the University of California, Davis, suggests that patients can also support their caretakers, and that reciprocated care has mutual benefits. A new paper published in the journal Aging and Mental Health highlights that couples coping with dementia can navigate the challenges with greater resilience and well-being by working together and supporting each other.
Company and financial neuro-rehab news
Building a global Alzheimer’s Disease testing infrastructure
Quanterix Corporation has announced a partnership path for laboratories interested in offering Tau based research and diagnostic testing services. Quanterix has secured over thirty U.S. patents protecting its ultra-sensitive research products and high-definition diagnostics. Those interested in building Alzheimer’s disease testing infrastructure should contact Quanterix to discuss potential partnership opportunities, including avenues for receiving a non-exclusive license to U.S. Patent No. 11,275,092, to measure Tau protein using Quanterix’s novel technique.
Policy, legislation and society news
FDA approves nonsteroidal treatment for Duchenne Muscular Dystrophy
The U.S. Food and Drug Administration approved Duvyzat (givinostat) oral medication for the treatment of Duchenne Muscular Dystrophy (DMD) in patients six years of age and older. Duvyzat is the first nonsteroidal drug approved to treat patients with all genetic variants of DMD. It is a histone deacetylase (HDAC) inhibitor that works by targeting pathogenic processes to reduce inflammation and loss of muscle.
